Pharmaceuticals, Biotechnology and Life Sciences
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of…
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on…
ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company,…
ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a…
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb.…
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026…
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative…
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D.,…
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that…